NRx Pharmaceuticals FDA Labeling Alignment

NRx Pharmaceuticals has received a letter from the FDA's Office of Generic Drugs indicating preliminary alignment on labeling for its preservative-free ketamine product. This development is a positive step towards regulatory approval for NRx's ketamine application. The alignment suggests the FDA finds the proposed labeling acceptable, potentially accelerating the path to market for this treatment. This milestone is crucial for the company as it seeks to commercialize its pharmaceutical innovations.